Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Two-Year Extension Follows Completion of $8 Million Upgrade and Preparation for Re-Launch of Alferon N in the US
Hemispherx Biopharma, Inc. (NYSE:HEB), announced that as the Company works toward the re-launch of Alferon N, it has extended its agreement with Armada Health Care, LLC for two years (through August 14 2017) for the sales/marketing of Alferon N Injection, its Food and Drug Administration approved natural interferon, in the U.S. Under this Agreement, the Company will manufacture and supply Alferon N Injection to physicians and patients through Armada’s national network of specialty pharmacies.
Armada has agreed to provide ongoing sales and marketing to support the product’s re-launch. Specialty Distributor, BioRidge Pharma, LLC, has received a two year contract extension and will warehouse, ship, and distribute Alferon N Injection on an exclusive basis for U.S. sales.
“We have closely followed Hemispherx progress in its major upgrade of the Alferon manufacturing facility and we are pleased that this is now complete and we can continue to work on preparing for the re-launch of Alferon N Injection. As the only natural interferon approved in the U.S., we think Alferon N Injection has great potential in our market”, stated Ryan Oligino, Executive Vice President Manufacturer Relations, Armada Health Care.
Wayne Springate, Senior Vice President of Operations for Hemispherx, stated “This extended agreement with Armada is gratifying. As leaders in the specialty pharmaceutical field, Armada is the ideal partner for the marketing and distribution of Alferon N Injection. Now with our upgrade work complete to include a high volume, state-of- the-art bioreactor for the manufacture of Alferon N Injection, we hope to be able to supply greater volumes of product to the market than in the past. We are also establishing an in-house team to support Armada and to establish other sales channels for Alferon N Injection, educate physicians and patients with the expectation to eventually drive sales in a growing and sustainable manner in the U.S., as well as in Europe, Latin America and Asia where we are actively seeking partners.”
About Armada Health Care:
Armada Health Care, LLC (Armada) is the industry’s largest specialty pharmacy group contracting and service organization. Armada provides comprehensive and cost-effective access to the nation’s $100+ billion specialty pharmacy industry. Armada offers pharmacy providers, manufacturers, health plans and wholesale distributors a total channel management solution through customized patient programs, prescription data management services, online platforms, and unique cost effective purchasing agreements on specialty pharmacy products. Armada is also the founder and host of the nation’s largest annual specialty pharmacy summit.
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is a specialty pharmaceutical company headquartered in Philadelphia, Pennsylvania and engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders.
